Liver Immune Tolerance Marker Utilization Study (LITMUS)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Previous pre-clinical work in the Levy Lab identified a novel biomarker gene set for the identification of tolerance in murine models of rapamycin-induced cardiac tolerance and spontaneous hepatic tolerance. Validation of this gene expression tolerance biomarker in operationally tolerant patients is now required for its implementation in the clinical setting. This proposal intends to validate and test our pre-clinically established tolerance gene expression biomarker in the clinical setting in order to translate our findings into improving the length and quality of life of transplant patients in the clinic.
The investigators hypothesize that a distinct gene expression profile expressed in the peripheral blood will identify operationally tolerant liver transplant recipients, allowing for the successful withdrawal of immunosuppression in these patients. Our study aims are: (I) To validate the pre-clinical gene expression profile for the identification of operationally tolerant liver recipients in plasma peripheral blood mononuclear cells (PBMCs) (2) To determine that the gene expression profile in the PBMCs is the same as the intra-graft gene expression profile (3) To demonstrate that liver transplant recipients with the tolerant gene expression profile can be safely weaned off of immunosuppression.
This proof of principle study will be conducted in two phases at the Toronto General Hospital (TGH) Phase 1 will address study aims 1 and 2, and phase 2 will address study aim 3. Potential participants will be screened and selected following predefined eligibility criteria. Eligible participants will undergo an informed consent process. The primary goal of this study is to validate the pre-clinical tolerant gene expression profile that will allow for the identification of tolerant liver recipients and for the monitored weaning off immunosuppression in these tolerant patients.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2C4
- Toronto General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
To be eligible to participate in this study, patients must:
- Be between 18 and 65 years of age.
- Be recipients of a hepatic allograft.
- Be less than 3 months post-transplant and be experiencing rejection, or be a minimum of 3 months post-transplant with or without presently experiencing rejection.
- Be healthy live liver donors
Exclusion Criteria:
Patients with the following conditions may not participate in the study:
- Patients under the age of 18 and over the age of 65.
- Patients who are positive for Human Immunodeficiency Virus (HIV),
- Patients who have detectable levels of HCV RNA, and HBV DNA, at the time of enrollment.
- Patients who have a combined transplant and/or have been re-transplanted.
- Patients taking immunosuppression for other diseases besides their liver transplant.
- Patients unable to give written informed consent in accordance with research ethics board guidelines.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Controlled weaning of immunosuppression
Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
|
At week 0 patients have liver biopsy and liver functional tests (LFTs).
Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA).
At week 4 LFTs.
Week 5-8 medication reduction to 1mg Tac / 100mg CsA.
Week 8 LFTs.
Week 9-12 reduction to 0.5mg Tac/ 50mg CsA.
Week 12 LFTs.
Week 13-16 reduction to 0mg.
Week 16 liver biopsy & LFTs.
Weekly LFTs performed Week 17-20.
Monthly LFTs for the next 3 months.
LFTs every 3 months for monitoring.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Validation of Tolerance Gene Expression Profile
Periodo de tiempo: Enrollment to one year post cessation of immunosuppression
|
The primary endpoint of this study is the identification and validation of a unique tolerance gene expression profile, consisting of a 6 gene profile, in 3-6 operationally tolerant patients compared to 25 rejecting and 25 healthy controls.
|
Enrollment to one year post cessation of immunosuppression
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Tolerance gene expression profile in graft versus peripheral blood mononuclear cells (PBMCs)
Periodo de tiempo: Enrollment to one year post cessation of immunosuppression
|
This endpoint will be defined as the ratio of patients (n=55) that will express the tolerance gene expression profile in the liver graft versus in the peripheral blood mononuclear cells.
|
Enrollment to one year post cessation of immunosuppression
|
|
Test of tolerance gene expression profile
Periodo de tiempo: Enrollment to one year post cessation of immunosuppression
|
This endpoint will assess whether the tolerance gene expression profile can be successfully used to select immunosuppressed patients for the successful weaning off immunosuppression.
This endpoint will be evaluated using the number of successful immunosuppression-weaned patients from a 7-10 patient cohort.
Successful immunosuppression-weaned patients are defined as patients who achieve an immunosuppression free state without any histological or clinical evidence of rejection for a minimum of 1 year.
|
Enrollment to one year post cessation of immunosuppression
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gary Levy, M.D., University Health Network, University of Toronto
- Silla de estudio: Leslie Lilly, M.D., University Health Network, Toronto
- Silla de estudio: Nazia Selzner, M.D. PhD., University Health Network, Toronto
- Director de estudio: Meaghan MacArthur, M.Ed, University Health Network, Toronto
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- Tol002
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .